Showing 1 - 8 results of 8 for search 'Ken Iseri', query time: 0.04s Refine Results
  1. 1
    Risk factors for blood vessel rupture during vascular access intervention therapy for hemodialysis patients.

    Risk factors for blood vessel rupture during vascular access intervention therapy for hemodialysis patients. by Yui Kambayashi, Ken Iseri, Tomoki Morikawa, Atushi Yao, Akio Yokochi, Hirokazu Honda

    Published 2023-01-01
    Get full text
    Article
  2. 2
    α-Blocker Use in Hemodialysis: The Japan Dialysis Outcomes and Practice Patterns Study

    α-Blocker Use in Hemodialysis: The Japan Dialysis Outcomes and Practice Patterns Study by Ken Iseri, Chisato Miyakoshi, Nobuhiko Joki, Yoshihiro Onishi, Shingo Fukuma, Hirokazu Honda, Kazuhiko Tsuruya

    Published 2023-09-01
    Get full text
    Article
  3. 3
    The effects of denosumab and alendronate on glucocorticoid-induced osteoporosis in patients with glomerular disease: A randomized, controlled trial.

    The effects of denosumab and alendronate on glucocorticoid-induced osteoporosis in patients with glomerular disease: A randomized, controlled trial. by Ken Iseri, Masayuki Iyoda, Makoto Watanabe, Kei Matsumoto, Daisuke Sanada, Takashi Inoue, Shohei Tachibana, Takanori Shibata

    Published 2018-01-01
    Get full text
    Article
  4. 4
    Serum uromodulin is associated with the severity of clinicopathological findings in ANCA-associated glomerulonephritis.

    Serum uromodulin is associated with the severity of clinicopathological findings in ANCA-associated glomerulonephritis. by Shohei Tachibana, Masayuki Iyoda, Taihei Suzuki, Nobuhiro Kanazawa, Ken Iseri, Yukihiro Wada, Kei Matsumoto, Takanori Shibata

    Published 2019-01-01
    Get full text
    Article
  5. 5
    Therapeutic Potential of Thrombomodulin in Renal Fibrosis of Nephrotoxic Serum Nephritis in Wistar-Kyoto Rats

    Therapeutic Potential of Thrombomodulin in Renal Fibrosis of Nephrotoxic Serum Nephritis in Wistar-Kyoto Rats by Nobuhiro Kanazawa, Masayuki Iyoda, Shohei Tachibana, Kei Matsumoto, Yukihiro Wada, Taihei Suzuki, Ken Iseri, Takanori Shibata

    Published 2020-03-01
    Get full text
    Article
  6. 6
    Clinical significance of serum and mesangial galactose-deficient IgA1 in patients with IgA nephropathy.

    Clinical significance of serum and mesangial galactose-deficient IgA1 in patients with IgA nephropathy. by Yukihiro Wada, Kei Matsumoto, Taihei Suzuki, Tomohiro Saito, Nobuhiro Kanazawa, Shohei Tachibana, Ken Iseri, Motonori Sugiyama, Masayuki Iyoda, Takanori Shibata

    Published 2018-01-01
    Get full text
    Article
  7. 7
    Anti-Phospholipase A2 Receptor (PLA2R) Antibody and Glomerular PLA2R Expression in Japanese Patients with Membranous Nephropathy.

    Anti-Phospholipase A2 Receptor (PLA2R) Antibody and Glomerular PLA2R Expression in Japanese Patients with Membranous Nephropathy. by Kei Hihara, Masayuki Iyoda, Shohei Tachibana, Ken Iseri, Tomohiro Saito, Yasutaka Yamamoto, Taihei Suzuki, Yukihiro Wada, Kei Matsumoto, Takanori Shibata

    Published 2016-01-01
    Get full text
    Article
  8. 8
    Epidermal growth factor receptor inhibition with erlotinib partially prevents cisplatin-induced nephrotoxicity in rats.

    Epidermal growth factor receptor inhibition with erlotinib partially prevents cisplatin-induced nephrotoxicity in rats. by Yukihiro Wada, Masayuki Iyoda, Kei Matsumoto, Yuki Shindo-Hirai, Yoshihiro Kuno, Yasutaka Yamamoto, Taihei Suzuki, Tomohiro Saito, Ken Iseri, Takanori Shibata

    Published 2014-01-01
    Get full text
    Article

Search Tools: